Free Trial

Insulet Q4 2022 Earnings Report

Insulet logo
$282.80 -5.49 (-1.90%)
As of 02/21/2025 04:00 PM Eastern

Insulet EPS Results

Actual EPS
$0.55
Consensus EPS
$0.24
Beat/Miss
Beat by +$0.31
One Year Ago EPS
$0.42

Insulet Revenue Results

Actual Revenue
$369.70 million
Expected Revenue
$331.73 million
Beat/Miss
Beat by +$37.97 million
YoY Revenue Growth
+20.10%

Insulet Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Insulet Earnings Headlines

Insulet: Aiding Patients And Investors
Trump doesn’t give a damn
Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…
Insulet price target raised to $293 from $245 at Stifel
Insulet price target raised to $325 from $317 at Morgan Stanley
Insulet (PODD) Receives a Hold from Stifel Nicolaus
See More Insulet Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Insulet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insulet and other key companies, straight to your email.

About Insulet

Insulet (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

View Insulet Profile

More Earnings Resources from MarketBeat